Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma
Caimi P, Huntington S, Landrette S, Gough S, Dai V, Jackson B, Yu T, Chavez J, Tannenbaum-Dvir S, Matasar M. Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood 2024, 144: 6505. DOI: 10.1182/blood-2024-208356.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaB-cell non-Hodgkin lymphomaDiffuse large B-cell lymphomaStem cell transplantationPhase 1 studyCell transplantationAdvanced B-cell non-Hodgkin's lymphomaB cellsMature B-cell non-Hodgkin lymphomaXenograft models of non-Hodgkin lymphomaBCL6 expressionEastern Cooperative Oncology Group performance statusModel of non-Hodgkin lymphomaAdvanced non-Hodgkin's lymphomaAllogeneic stem cell transplantationAngioimmunoblastic T-cell lymphomaAutologous stem cell transplantationLarge B-cell lymphomaNon-Hodgkin's lymphoma casesCell line-derived xenograft modelT follicular helper cellsPatient-derived xenograft modelsStandard of care therapyHigh risk of transformationCentral nervous system involvement